Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. South Africa
  4. Johannesburg Stock Exchange
  5. Discovery Limited
  6. News
  7. Summary
    DSY   ZAE000022331

DISCOVERY LIMITED

(DSY)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

S.African health insurer Discovery in touch with vaccine makers

03/29/2021 | 10:55am EDT

JOHANNESBURG, March 29 (Reuters) - South African health insurer Discovery Ltd said on Monday it was in contact with all COVID-19 vaccine producers but cannot independently source vaccines as procurement and distribution is in the hands of the government.

As in many countries, vaccine procurement in South Africa is centralised and controlled by government but the pace of procurement and inoculation has been slow, with less than 250,000 people, or just 0.5% of the population vaccinated so far.

This has prompted calls from health experts to allow the private sector to source vaccines to bolster government efforts.

"While we (Discovery) might be in contact with vaccine manufacturers, the acquisition of the vaccine and the policy for who receives it and in what sequence remains the exclusive responsibility of government, until such time as government informs otherwise," said Ryan Noach, CEO of the company's medical scheme administrator Discovery Health.

"We have been in regular liaison with vaccine manufacturers since September 2020," Noach said in an emailed response to Reuters. He said the company is taking all measures to "ensure the procurement is efficient, and stock available quickly, especially for the most at risk."

South Africa's vaccine rollout faced a blow in early February when it decided to halt the rollout of AstraZeneca's shots on concerns about its effectiveness against the 501Y.V2 variant that caused a huge spurt in infections late last year.

The country has since opted for Johnson & Johnson's vaccine under an "implementation study."

In a note to the members on Friday, Discovery's group CEO Adrian Gore said the company was aiming to vaccinate its three million adult members, with the capacity of 50,000 vaccinations per day starting in May, if vaccine supplies are on time.

"This will enable all of Discovery's 550,000 high-risk members to be vaccinated within a few weeks," he said.

South Africa's Health Ministry did not immediately respond to Reuters request for comment when asked about private vaccine procurement. (Reporting by Promit Mukherjee. Editing by Jane Merriman)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.22% 8795 Delayed Quote.20.08%
DISCOVERY LIMITED 0.24% 135.27 End-of-day quote.-11.90%
DOW JONES AFRICA TITANS 50 INDEX 1.07% 550.53 Delayed Quote.4.05%
DOW JONES SOUTH AFRICA(ZAR) 0.28% 1922.35 Delayed Quote.9.00%
S&P AFRICA 40 INDEX 0.54% 176.71 Delayed Quote.2.14%
All news about DISCOVERY LIMITED
09/02Discovery Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
09/02DISCOVERY : S.Africa's Discovery scraps dividend, flags possible capital raise
RE
08/12Discovery Limited Appoints Monhla Hlahla as an Independent Non-Executive Director and a..
CI
07/09MARKET CHATTER : HSBC Chair Refuses To Discuss Hong Kong Security Law With International A..
MT
06/29How Beijing humbled Britain's mighty HSBC
RE
06/07HSBC Replaces Top Executive in Asia -- 3rd Update
DJ
06/07HSBC Replaces Top Executive in Asia -- 2nd Update
DJ
06/07HSBC Replaces Top Executive in Asia -- Update
DJ
03/29S.African health insurer Discovery in touch with vaccine makers
RE
03/29S.African health insurer Discovery in touch with vaccine makers
RE
More news
Financials
Sales 2022 52 442 M 3 593 M 3 593 M
Net income 2022 6 517 M 447 M 447 M
Net Debt 2022 20 562 M 1 409 M 1 409 M
P/E ratio 2022 13,8x
Yield 2022 1,45%
Capitalization 88 846 M 6 076 M 6 087 M
EV / Sales 2022 2,09x
EV / Sales 2023 2,05x
Nbr of Employees -
Free-Float 61,4%
Chart DISCOVERY LIMITED
Duration : Period :
Discovery Limited Technical Analysis Chart | DSY | ZAE000022331 | MarketScreener
Technical analysis trends DISCOVERY LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 135,27 ZAR
Average target price 167,50 ZAR
Spread / Average Target 23,8%
EPS Revisions
Managers and Directors
Adrian Gore Group Chief Executive Officer & Executive Director
Deon Marius Viljoen Chief Financial Officer & Executive Director
Mark Edward Tucker Chairman
Brian Antony Brink Independent Non-Executive Director
Thabane Vincent Maphai Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
DISCOVERY LIMITED-11.90%6 076
AXA22.62%66 275
METLIFE, INC.39.66%56 187
PRUDENTIAL PLC7.98%54 701
PRUDENTIAL FINANCIAL, INC.41.65%42 776
MANULIFE FINANCIAL CORPORATION10.42%39 269